Literature DB >> 30092366

8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.

Cyril Fersing1, Clotilde Boudot2, Julien Pedron3, Sébastien Hutter4, Nicolas Primas1, Caroline Castera-Ducros1, Sandra Bourgeade-Delmas5, Alix Sournia-Saquet3, Alain Moreau3, Anita Cohen4, Jean-Luc Stigliani3, Geneviève Pratviel3, Maxime D Crozet1, Susan Wyllie6, Alan Fairlamb6, Alexis Valentin5, Pascal Rathelot1, Nadine Azas4, Bertrand Courtioux2, Pierre Verhaeghe7, Patrice Vanelle8.   

Abstract

Based on a previously identified antileishmanial 6,8-dibromo-3-nitroimidazo[1,2-a]pyridine derivative, a Suzuki-Miyaura coupling reaction at position 8 of the scaffold was studied and optimized from a 8-bromo-6-chloro-3-nitroimidazo[1,2-a]pyridine substrate. Twenty-one original derivatives were prepared, screened in vitro for activity against L. infantum axenic amastigotes and T. brucei brucei trypomastigotes and evaluated for their cytotoxicity on the HepG2 human cell line. Thus, 7 antileishmanial hit compounds were identified, displaying IC50 values in the 1.1-3 μM range. Compounds 13 and 23, the 2 most selective molecules (SI = >18 or >17) were additionally tested on both the promastigote and intramacrophage amastigote stages of L. donovani. The two molecules presented a good activity (IC50 = 1.2-1.3 μM) on the promastigote stage but only molecule 23, bearing a 4-pyridinyl substituent at position 8, was active on the intracellular amastigote stage, with a good IC50 value (2.3 μM), slightly lower than the one of miltefosine (IC50 = 4.3 μM). The antiparasitic screening also revealed 8 antitrypanosomal hit compounds, including 14 and 20, 2 very active (IC50 = 0.04-0.16 μM) and selective (SI = >313 to 550) molecules toward T. brucei brucei, in comparison with drug-candidate fexinidazole (IC50 = 0.6 & SI > 333) or reference drugs suramin and eflornithine (respective IC50 = 0.03 and 13.3 μM). Introducing an aryl moiety at position 8 of the scaffold quite significantly increased the antitrypanosomal activity of the pharmacophore. Antikinetoplastid molecules 13, 14, 20 and 23 were assessed for bioactivation by parasitic nitroreductases (either in L. donovani or in T. brucei brucei), using genetically modified parasite strains that over-express NTRs: all these molecules are substrates of type 1 nitroreductases (NTR1), such as those that are responsible for the bioactivation of fexinidazole. Reduction potentials measured for these 4 hit compounds were higher than that of fexinidazole (-0.83 V), ranging from -0.70 to -0.64 V. Crown
Copyright © 2018. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  HepG2 cytotoxicity; Imidazo[1,2-a]pyridine; In vitro activity; Leishmania; Nitroheterocycles; Nitroreductases; Redox potentials; SARs; Suzuki-Miyaura cross-coupling reaction; Trypanosoma

Mesh:

Substances:

Year:  2018        PMID: 30092366      PMCID: PMC7089781          DOI: 10.1016/j.ejmech.2018.07.064

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  29 in total

1.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.

Authors:  B Räz; M Iten; Y Grether-Bühler; R Kaminsky; R Brun
Journal:  Acta Trop       Date:  1997-11       Impact factor: 3.112

2.  Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.

Authors:  Susan Wyllie; Stephen Patterson; Alan H Fairlamb
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

Review 3.  Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness).

Authors:  Peter Ge Kennedy
Journal:  Lancet Neurol       Date:  2012-12-21       Impact factor: 44.182

4.  An essential type I nitroreductase from Leishmania major can be used to activate leishmanicidal prodrugs.

Authors:  Andrew A Voak; Vithurshaa Gobalakrishnapillai; Karin Seifert; Edina Balczo; Longqin Hu; Belinda S Hall; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

Review 5.  Neglected tropical diseases: progress towards addressing the chronic pandemic.

Authors:  David H Molyneux; Lorenzo Savioli; Dirk Engels
Journal:  Lancet       Date:  2016-09-14       Impact factor: 79.321

6.  Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense.

Authors:  T Baltz; D Baltz; C Giroud; J Crockett
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

7.  Regioselective Suzuki-Miyaura reaction: application to the microwave-promoted synthesis of 4,7-diarylquinazolines.

Authors:  Youssef Kabri; Pierre Verhaeghe; Armand Gellis; Patrice Vanelle
Journal:  Molecules       Date:  2010-04-27       Impact factor: 4.411

Review 8.  Human African trypanosomiasis.

Authors:  Philippe Büscher; Giuliano Cecchi; Vincent Jamonneau; Gerardo Priotto
Journal:  Lancet       Date:  2017-06-30       Impact factor: 79.321

Review 9.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects.

Authors:  Stephen Patterson; Susan Wyllie
Journal:  Trends Parasitol       Date:  2014-04-26

10.  Regiocontrolled microwave assisted bifunctionalization of 7,8-dihalogenated imidazo[1,2-a]pyridines: a one pot double-coupling approach.

Authors:  Emilie Marie; Sébastien Bouclé; Cécile Enguehard-Gueiffier; Alain Gueiffier
Journal:  Molecules       Date:  2012-09-06       Impact factor: 4.411

View more
  4 in total

1.  Nongenotoxic 3-Nitroimidazo[1,2-a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity.

Authors:  Cyril Fersing; Louise Basmaciyan; Clotilde Boudot; Julien Pedron; Sébastien Hutter; Anita Cohen; Caroline Castera-Ducros; Nicolas Primas; Michèle Laget; Magali Casanova; Sandra Bourgeade-Delmas; Mélanie Piednoel; Alix Sournia-Saquet; Valère Belle Mbou; Bertrand Courtioux; Élisa Boutet-Robinet; Marc Since; Rachel Milne; Susan Wyllie; Alan H Fairlamb; Alexis Valentin; Pascal Rathelot; Pierre Verhaeghe; Patrice Vanelle; Nadine Azas
Journal:  ACS Med Chem Lett       Date:  2018-12-19       Impact factor: 4.345

2.  Improving Aqueous Solubility and In Vitro Pharmacokinetic Properties of the 3-Nitroimidazo[1,2-a]pyridine Antileishmanial Pharmacophore.

Authors:  Romain Paoli-Lombardo; Nicolas Primas; Sandra Bourgeade-Delmas; Sébastien Hutter; Alix Sournia-Saquet; Clotilde Boudot; Emilie Brenot; Caroline Castera-Ducros; Sophie Corvaisier; Marc Since; Aurélie Malzert-Fréon; Bertrand Courtioux; Alexis Valentin; Pierre Verhaeghe; Nadine Azas; Pascal Rathelot; Patrice Vanelle
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-13

Review 3.  Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents.

Authors:  Prisca Lagardère; Cyril Fersing; Nicolas Masurier; Vincent Lisowski
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-27

Review 4.  Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review.

Authors:  Anita Cohen; Nadine Azas
Journal:  Pathogens       Date:  2021-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.